Elite in Lung Cancer

Nong Yang

No.87 Xiangya Road, 
Changsha, CN 
Clinical Trials:Currently Recruiting for 2 Trials
Elite in Lung Cancer
No.87 Xiangya Road, 
Changsha, CN 
OverviewLocationsClinical Research

Overview

Nong Yang practices in Changsha, China. Mr. Yang is rated as an Elite expert by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Tissue Biopsy, and Gastrectomy.

His clinical research consists of co-authoring 181 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 155 articles and participated in 14 clinical trials in the study of Lung Cancer.

Gender
Male

Locations

No.87 Xiangya Road, Changsha, 410008, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib in ROS1-rearranged Non-squamous Non-small Cell Lung Cancer
A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib in ROS1-rearranged Non-squamous Non-small Cell Lung Cancer
Enrollment Status: Recruiting
Publish Date: December 27, 2023
Intervention Type: Drug
A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib in ALK Rearranged Advanced Non Squamous Non-small Cell Lung Cancer
A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib in ALK Rearranged Advanced Non Squamous Non-small Cell Lung Cancer
Enrollment Status: Recruiting
Publish Date: December 27, 2023
Intervention Type: Drug
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Tepotinib, Osimertinib
Study Phase: Phase 2
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: X-396 (Ensartinib), Crizotinib
Study Phase: Phase 3
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
Multicenter, Open-label, Phase II Study With a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïve
Multicenter, Open-label, Phase II Study With a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïve
Enrollment Status: Active_not_recruiting
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drugs: Encorafenib, Binimetinib
Study Phase: Phase 2
A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Tislelizumab+Cisplatin or Carboplatin+Pemetrexed, Cisplatin or Carboplatin+Pemetrexed
Study Phase: Phase 3
A Phase II Study on Toripalimab Combined With Double Platinum Based Chemotherapy for as a Neoadjuvant Therapy for Initially Unresectable Non-driver Gene Mutation Non-small Cell Lung Cancer
A Phase II Study on Toripalimab Combined With Double Platinum Based Chemotherapy for as a Neoadjuvant Therapy for Initially Unresectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drug: Treprilumab+Platinum based chemotherapy
Study Phase: Phase 2
A Multi-center, Single Arm , Phase II Study of Atezolizumab Combined With Concurrent Chemoradiotherapy and Maintenance Therapy With Atezolizumab in Untreated Participants With Extensive-stage Small Cell Lung Cancer
A Multi-center, Single Arm , Phase II Study of Atezolizumab Combined With Concurrent Chemoradiotherapy and Maintenance Therapy With Atezolizumab in Untreated Participants With Extensive-stage Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: June 14, 2022
Intervention Type: Procedure
Study Phase: Phase 2
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Enrollment Status: Completed
Publish Date: June 14, 2022
Intervention Type: Drug
Study Phase: Phase 3
Single Center, Single Arm Phase II Study on Efficacy Evaluation and Bio-marker Analysis of Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer
Single Center, Single Arm Phase II Study on Efficacy Evaluation and Bio-marker Analysis of Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Drug
Study Drug: Sintilimab+Docetaxel
Study Phase: Phase 2
Multiple-center, Single-arm, Phase II Study on Sintilimab Combined With Docetaxel in Non-driver Gene Mutation Advanced NSCLC Patients Who Had Failed With Double Platinum-based Chemotherapy
Multiple-center, Single-arm, Phase II Study on Sintilimab Combined With Docetaxel in Non-driver Gene Mutation Advanced NSCLC Patients Who Had Failed With Double Platinum-based Chemotherapy
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Drug
Study Drug: Sintilimab+Docetaxel Monotherapy
Study Phase: Phase 2
A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma
A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma
Enrollment Status: Unknown
Publish Date: December 13, 2021
Intervention Type: Biological
Study Drug: JS001 Anti-PD-1 Antibody
Study Phase: Phase 1/Phase 2
Serum Thioredoxin Reductase Activity Research in First-line Chemotherapy Advanced Non-small Cell Lung Cancer
Serum Thioredoxin Reductase Activity Research in First-line Chemotherapy Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 26, 2020
the Effectiveness and Safety Study on Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer
the Effectiveness and Safety Study on Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 14 Less Clinical Trials

181 Total Publications

PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.
Journal: Nature communications
Published: September 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Yang's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile